Weekly Pharma & Life Science News Round-Up: 31st October – 4th November
A round-up of the latest news from the Life Science industry; including news from the Pharmaceutical, Clinical Research, Biotechnology and Medical Device sectors from 31st October – 4th November.
Thermo Fisher Scientific Inc., the world leader in serving science, and Society for Science (the Society), announces the Thermo Fisher Scientific Junior Innovators Challenge, the nation’s premier middle school science, technology, engineering and math (STEM) competition.
MIMETAS Elected Most Innovative Company of the Netherlands
MIMETAS is the winner of the Dutch Innovation Award 2022. This award recognizes the company's considerable focus on innovation, contribution to the reduction of animal experimentation, leadership, organization, cooperation with partners, and market position.
Johnson & Johnson to Acquire Abiomed
Johnson & Johnson and Abiomed announce that they have entered into a definitive agreement under which Johnson & Johnson will acquire through a tender offer all outstanding shares of Abiomed.
Biotechnology startup Longenesis has partnered with Dante Genomics, a global leader in genomics and precision medicine, to offer whole genome sequencing (WGS) to more than 10,000 existing Longenesis study participants.
Thermo Fisher Scientific to Acquire The Binding Site Group
Thermo Fisher Scientific Inc. announce that it has entered into a definitive agreement to acquire The Binding Site Group from a shareholder group led by European private equity firm Nordic Capital, in an all-cash transaction valued at £2.25 billion, or $2.6 billion at current exchange rates.
Citeline and Norstella Complete Merger to Form a $5 Billion Global Pharmaceutical Technology Company
Norstella, a global leader with end-to-end solutions that smooth access to life-saving therapies for patients, has announced the completion of its merger with Citeline (formerly Pharma Intelligence), a leader in the clinical trial intelligence space.
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Society for Science (the Society), announce the Thermo Fisher Scientific Junior Innovators Challenge, the nation’s premier middle school science, technology, engineering and math (STEM) competition.
Vizgen Wins “Overall BioTech Company of the Year” in 2022 BioTech Breakthrough Awards Program
Vizgen announces it has been named “Overall BioTech Company of the Year” in the second annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization.
Sia Partners Accelerates in the Life Sciences Sector with the Acquisition of Latham BioPharm Group
Sia Partners is accelerating its growth with the launch of a division dedicated to Life Science Consulting, thanks to the acquisition of Latham BioPharm Group (LBG), a comprehensive team of nearly 60 life science consultants with recognized global Life Sciences expertise, founded in 1996.
Aptar Again Named a Global Top Female-Friendly Company by Forbes
AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announces it has again been named one of the World’s Top Female-Friendly Companies by Forbes.
AbCellera (Nasdaq: ABCL) announced today that Regeneron has elected to exercise its right to advance a therapeutic antibody candidate, discovered in partnership with AbCellera as part of a multi-target collaboration between the companies, into further preclinical development.
Ligand Announces Completion of OmniAb Spin-Off
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the company has completed the expected tax-free spin-off of its OmniAb antibody discovery business which has become OmniAb, Inc., an independent publicly traded company.
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
Arcturus Therapeutics Holdings Inc. announceds a strategic collaboration with CSL Seqirus, a global vaccine leader, for the research, development, manufacture, and global commercialization of vaccines.
Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), announces its launch with $120 million in financing.
Memo Therapeutics AG (“MTx”), an innovator in the field of antibody discovery and development, announces the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd (“Ono”).
